Ipamorelin

Mechanism of action

Ipamorelin binds to the GHSR-1a receptor expressed at the hypothalamic and pituitary levels. Activation of GHSR-1a increases GH secretion (typically in a pulsatile manner), with a potential secondary increase in hepatic IGF-1 depending on dose, frequency, and physiological status. Compared with other GHSs, it is often described as relatively selective for GH, with less stimulation of ACTH/cortisol and prolactin in some models; this does not eliminate the possibility of indirect endocrine effects (e.g., on insulin sensitivity, fluid retention, carbohydrate metabolism) mediated by the GH/IGF-1 axis.

Supported benefits

• Acute increase in GH secretion (pharmacodynamic response) under experimental conditions (moderate)
• Possible increase in IGF-1 with repeated protocols (dose- and duration-dependent), with high interindividual variability (limited)
• Clinically significant and consistent improvements in body composition, performance, or recovery in healthy subjects (emerging)

Safety & side effects

• Injection-site reactions (pain, erythema, swelling), risk of infection/abscess if non-sterile practices are used.
• Headache, flushing, nausea, or dizziness (variable reports).
• Fluid retention/edema and paresthesias: possible with increased GH/IGF-1 activity, especially with repeated exposure.
• Alterations in carbohydrate metabolism (reduced insulin sensitivity, changes in blood glucose) potentially related to the GH/IGF-1 axis.
• Possible changes in appetite via the ghrelin/GHSR axis (not always predictable).

FAQ

Is Ipamorelin a dietary supplement?

No. It is a synthetic peptide studied in the pharmacological field; it is not a nutrient and does not have adequate oral bioavailability. Its sale as a “supplement” is often improper or non-compliant with local regulations.

Does it really increase growth hormone?

In experimental studies it can acutely increase GH secretion via GHSR-1a. This does not automatically imply clinically meaningful or safe benefits in healthy subjects.

Is it “safer” than other GH secretagogues?

Some data suggest relatively more selective stimulation of GH compared with other GHSs, but this does not equate to guaranteed safety: endocrine and metabolic risks remain, as do risks related to product quality and route of administration.

What are the main practical risks?

In addition to systemic effects (blood glucose, fluid retention), a concrete risk is the use of non-sterile or impure products and injection-related complications. Lack of quality control is a determining factor.

Can it influence cancer risk?

The GH/IGF-1 axis has pro-growth and pro-proliferative effects in various tissues. It is not possible to draw conclusions about individual risk without clinical context, but in the presence of active or suspected neoplasms, a strong precautionary principle applies.